免疫性血小板减少症：耐受性丧失。 - Suppr

Suppr

超能文献

ITP: tolerance lost.

作者信息

Fogarty Patrick F

机构信息

University of Pennsylvania, USA.

出版信息

Blood. 2011 Dec 8;118(24):6232-4. doi: 10.1182/blood-2011-10-383893.

DOI:10.1182/blood-2011-10-383893

PMID:22161847

Abstract

摘要

相似文献

ITP: tolerance lost.

Blood. 2011 Dec 8;118(24):6232-4. doi: 10.1182/blood-2011-10-383893.

A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.

Blood. 2011 Dec 8;118(24):6299-305. doi: 10.1182/blood-2011-08-371138. Epub 2011 Sep 29.

Acute pneumonitis and pericarditis related to alemtuzumab therapy in relapsing-remitting multiple sclerosis.

J Neurol. 2017 Jan;264(1):168-169. doi: 10.1007/s00415-016-8306-x. Epub 2016 Nov 25.

Pancolitis a novel early complication of Alemtuzumab for MS treatment.

Mult Scler Relat Disord. 2016 May;7:83-4. doi: 10.1016/j.msard.2016.03.014. Epub 2016 Mar 30.

Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.

Immunotherapy. 2014;6(3):249-59. doi: 10.2217/imt.14.7.

Ocrelizumab (Ocrevus) for MS.

Med Lett Drugs Ther. 2017 Jun 19;59(1523):98-101.

Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management.

Mult Scler. 2020 Jan;26(1):48-56. doi: 10.1177/1352458518816612. Epub 2019 Feb 20.

Fingolimod-induced immune thrombocytopenic purpura (ITP).

Clin Neurol Neurosurg. 2020 Oct;197:106081. doi: 10.1016/j.clineuro.2020.106081. Epub 2020 Jul 10.

Alemtuzumab-induced red cell aplasia and other immune cytopenias: not so 'pure'.

Immunotherapy. 2022 Feb;14(2):95-99. doi: 10.2217/imt-2021-0163. Epub 2021 Nov 8.

Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis.

Mult Scler. 2012 Aug;18(8):1197-9. doi: 10.1177/1352458511435716. Epub 2012 Jan 17.

引用本文的文献

Aberrant Expression of a Proliferation-Inducing Ligand Underlies Autoimmune Mechanisms in Immune Thrombocytopenia.

J Immunol Res. 2021 Jan 30;2021:3676942. doi: 10.1155/2021/3676942. eCollection 2021.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

ITP: tolerance lost.

Blood. 2011 Dec 8;118(24):6232-4. doi: 10.1182/blood-2011-10-383893.

A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.

Blood. 2011 Dec 8;118(24):6299-305. doi: 10.1182/blood-2011-08-371138. Epub 2011 Sep 29.

Acute pneumonitis and pericarditis related to alemtuzumab therapy in relapsing-remitting multiple sclerosis.

J Neurol. 2017 Jan;264(1):168-169. doi: 10.1007/s00415-016-8306-x. Epub 2016 Nov 25.

Pancolitis a novel early complication of Alemtuzumab for MS treatment.

Mult Scler Relat Disord. 2016 May;7:83-4. doi: 10.1016/j.msard.2016.03.014. Epub 2016 Mar 30.

Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.

Immunotherapy. 2014;6(3):249-59. doi: 10.2217/imt.14.7.

Ocrelizumab (Ocrevus) for MS.

Med Lett Drugs Ther. 2017 Jun 19;59(1523):98-101.

Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management.

Mult Scler. 2020 Jan;26(1):48-56. doi: 10.1177/1352458518816612. Epub 2019 Feb 20.

Fingolimod-induced immune thrombocytopenic purpura (ITP).

Clin Neurol Neurosurg. 2020 Oct;197:106081. doi: 10.1016/j.clineuro.2020.106081. Epub 2020 Jul 10.

Alemtuzumab-induced red cell aplasia and other immune cytopenias: not so 'pure'.

Immunotherapy. 2022 Feb;14(2):95-99. doi: 10.2217/imt-2021-0163. Epub 2021 Nov 8.

Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis.

Mult Scler. 2012 Aug;18(8):1197-9. doi: 10.1177/1352458511435716. Epub 2012 Jan 17.

引用本文的文献

Aberrant Expression of a Proliferation-Inducing Ligand Underlies Autoimmune Mechanisms in Immune Thrombocytopenia.

J Immunol Res. 2021 Jan 30;2021:3676942. doi: 10.1155/2021/3676942. eCollection 2021.